Literature DB >> 17483547

Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.

Jane Freeman1, Simon D Baines, Katie Saxton, Mark H Wilcox.   

Abstract

OBJECTIVES: We compared the behaviour of Clostridium difficile PCR ribotypes 001 and 027 in a human gut model, and compared the responses to metronidazole exposure.
METHODS: Using a human gut model primed with pooled human faeces, gut flora bacterial counts, C. difficile total viable counts, spore counts and cytotoxin titres were determined, following exposure to clindamycin, in the absence or presence of metronidazole.
RESULTS: Duration of cytotoxin production by C. difficile ribotype 027 was markedly longer than that of ribotype 001 (23 versus 13 days, respectively), but peak toxin titres were similar. During toxin production, total C. difficile ribotype 027 populations had higher proportions of vegetative cells than did ribotype 001 (median 56.33 versus 23.54%). Similarly, total C. difficile ribotype 027 populations remained predominantly as vegetative cells for longer than did ribotype 001 (20 versus 9 days). The effects of metronidazole on C. difficile were markedly less than expected. Titres of C. difficile ribotype 001 cytotoxin were reduced but recurred following metronidazole administration. C. difficile ribotype 027 cytotoxin titres in the distal section of the gut model were unaffected by metronidazole. These observations correlated with poor metronidazole concentrations.
CONCLUSIONS: Duration of cytotoxin production by C. difficile ribotype 027 markedly exceeds that of ribotype 001. Sub-optimal gut concentrations of metronidazole, possibly due to inactivation by components of normal gut flora, are associated with continued toxin production. These findings may help to explain the increased severity of symptoms and higher case-fatality ratio associated with infections due to C. difficile ribotype 027.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483547     DOI: 10.1093/jac/dkm113

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  30 in total

1.  Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.

Authors:  April Roberts; Joanna McGlashan; Ibrahim Al-Abdulla; Roger Ling; Harriet Denton; Steve Green; Ruth Coxon; John Landon; Clifford Shone
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Authors:  Thomas Akerlund; Ingela Persson; Magnus Unemo; Torbjörn Norén; Bo Svenungsson; Marlene Wullt; Lars G Burman
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

3.  Can metronidazole still be used for treatment of Clostridium difficile infections?

Authors:  Haihui Huang; Carl Erik Nord
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

4.  Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.

Authors:  Michelle Merrigan; Anilrudh Venugopal; Michael Mallozzi; Bryan Roxas; V K Viswanathan; Stuart Johnson; Dale N Gerding; Gayatri Vedantam
Journal:  J Bacteriol       Date:  2010-07-30       Impact factor: 3.490

Review 5.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

6.  Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon.

Authors:  Mary C Rea; Alleson Dobson; Orla O'Sullivan; Fiona Crispie; Fiona Fouhy; Paul D Cotter; Fergus Shanahan; Barry Kiely; Colin Hill; R Paul Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-29       Impact factor: 11.205

7.  Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.

Authors:  Alex Carignan; Sébastien Poulin; Philippe Martin; Annie-Claude Labbé; Louis Valiquette; Hamed Al-Bachari; Louis-Philippe Montpetit; Jacques Pépin
Journal:  Am J Gastroenterol       Date:  2016-09-13       Impact factor: 10.864

8.  Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic ribotype 027 strains.

Authors:  W N Fawley; J Freeman; C Smith; C Harmanus; R J van den Berg; E J Kuijper; M H Wilcox
Journal:  J Clin Microbiol       Date:  2008-01-23       Impact factor: 5.948

9.  Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1.

Authors:  David Goulding; Harold Thompson; Jenny Emerson; Neil F Fairweather; Gordon Dougan; Gill R Douce
Journal:  Infect Immun       Date:  2009-09-14       Impact factor: 3.441

10.  Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A.

Authors:  Ruth Murray; Dave Boyd; Paul N Levett; Michael R Mulvey; Michelle J Alfa
Journal:  BMC Infect Dis       Date:  2009-06-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.